Changes in Beneficial Ownership · 4
AbCellera Biologics Inc.
ABCLNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1786723463.xml
Filing details
- Report period
- 2026-08-14
- Issuer
- AbCellera Biologics Inc.
- Issuer CIK
- 0001703057
- Trading symbol
- ABCL
Reporting owner 1
- Name
- Booth Andrew
- Reporting owner CIK
- 0001834411
- Relationship
- Officer
- Officer title
- Chief Financial Officer
- Address
- C/O ABCELLERA BIOLOGICS INC, 150 W 4TH AVENUE, VANCOUVER, BRITISH COLUMBIA, CANADA, A1
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Timeliness |
|---|---|---|---|---|---|---|---|---|
| Common Shares | 2026-08-14 | P · Form 5 | 37,200 | A | 10.32 | 482,800 | D | E |
Table key
- P · Form 5
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Shares | 130,959 | I | By spouse |
Table key
- I
- Indirect
Signature 1
- Signed
- Tryn Stimart, attorney-in-fact
- Date
- 2026-08-14
Company context
AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more.